Allied Healthcare Group Ltd was established in June 2011,
through the merger of Allied Medical Ltd an unlisted public company
and bioMD Ltd an ASX listed company (ASX: BOD).
The merger created a diversified healthcare group with assets in
research & development, products in advanced clinical trials
ready for commercialisation and a successful sales, marketing and
medical device distribution business.
Listed on the ASX in 2004, bioMD acquired and has successfully
developed the assets of regenerative tissue engineering company
Celxcel.
Allied Medical Ltd was originally spun out of Fortescue Metals Group Limited (FMG) and became an independent entity in November 2005.
Allied’s growth strategy has been founded upon leveraging its core competencies in sales, distribution and commercialisation to support its investments in growth areas – sectors identified as having the potential to make a significant and positive contribution in the healthcare sector.
In 2008, Allied identified a partnership to gain entry in the growing vaccine market with a right to acquire a majority shareholding in Coridon Pty Ltd (Coridon), a company founded by Professor Ian Frazer, Australian of the Year 2006. Professor Frazer is well recognised for his ground breaking research that led to Merck & Co.’s highly successful cervical cancer vaccine, Gardasil®.
The Coridon partnership fitted well with Allied’s long term strategic goal of creating shareholder value through identifying opportunities and investing in innovative technologies that have global potential with world class research expertise.
In 2010, the Allied expanded its sales and distribution business with the acquisition of Medevco Pty Ltd. Medevco is an Australian-based supplier and distributor of medical devices and has a sales, marketing, logistics and technical service footprint across Australia and New Zealand.
Allied Healthcare Group is listed on the Australian Securities Exchange under the code: AHZ